425: Aerovate Therapeutics to Acquire Jade Biosciences in Merger Deal

Aerovate Therapeutics is set to acquire Jade Biosciences through a merger, aiming to expand its pipeline with Jade's autoimmune disease therapies.

Summary

• Aerovate Therapeutics and Jade Biosciences have entered into a merger agreement.
• Aerovate will acquire Jade through a series of mergers involving subsidiary entities.
• Jade Biosciences is focused on developing therapies for autoimmune diseases, particularly IgA nephropathy (IgAN).
• Jade's lead candidate, JADE-001, is a potential best-in-class anti-APRIL mAb for IgAN, targeting a market estimated to exceed $10 billion annually in the US.
• Jade has raised approximately $300 million to date, including proceeds from a pre-closing private financing.
• Post-merger, the estimated total shares of the combined company will be 1,855,835,012.
• Aerovate expects to declare a cash dividend to pre-merger Aerovate stockholders, estimated to be approximately $65 million or $2.25 per share.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger and the potential of JADE-001, but acknowledges the inherent risks and uncertainties associated with drug development and regulatory approvals. The emphasis on 'best-in-class' potential and a large market opportunity contributes to the positive sentiment.

Positives

• Jade Biosciences has a promising lead candidate, JADE-001, targeting a significant unmet need in IgAN treatment.
• JADE-001's design aims for superior potency and extended half-life, potentially leading to less frequent dosing and improved patient compliance.
• The merger provides Jade with access to Aerovate's resources and expertise.
• Jade has a pipeline of additional programs focused on high-value Inflammation and Immunology (I&I) indications.
• The company has raised significant capital from top-tier healthcare investors.

Negatives

• JADE-001 is still in early stages of development, with healthy volunteer data expected in 1H 2026.
• The success of JADE-001 is dependent on achieving desired clinical outcomes, including IgA reduction and proteinuria reduction.
• The document contains forward-looking statements that are subject to risks and uncertainties.
• The merger is subject to customary closing conditions, including Aerovate stockholder approval.

Risks

• The forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• The merger is subject to conditions, including Aerovate stockholder approval and the completion of the concurrent investment.
• There are risks related to estimating operating expenses and the impact of delays on the combined company's cash resources.
• The combined company faces risks related to intellectual property protection and competitive responses.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.

Future Outlook

The combined company will focus on developing and commercializing therapies for autoimmune diseases, with JADE-001 as the lead candidate for IgAN. The company anticipates initiating Phase 1 trials for JADE-001 in 1H 2026 and expects healthy volunteer data in the same period.

Management Comments

• European KOL: 'The APRIL class will be the backbone [of therapy]. This class will become first-line.'
• US KOL: 'These therapies may change the thinking in IgAN. Instead of first starting with a hemodynamic agent and then going to prednisone now we would start with [anti-APRIL and anti-APRIL/BAFF].'
• US KOL: 'If I biopsy a patient and they have clear inflammation, if these were available, I would use them immediately with ACEi / ARBs.'

Industry Context

The merger reflects a growing interest in autoimmune disease therapies, particularly in IgAN, where there is a high unmet need for disease-modifying treatments. Several companies are developing anti-APRIL and TACI-Fc therapies for IgAN, indicating a competitive landscape.

Comparison to Industry Standards

• JADE-001 is positioned as a potential best-in-class anti-APRIL mAb, aiming for superior potency and half-life compared to existing and investigational therapies like sibeprenlimab, zigakibart, atacicept and povetacicept.
• The document highlights JADE-001's potential for less frequent dosing (Q8W+) compared to sibeprenlimab (Q4W) and zigakibart (Q2W).
• The presentation compares proteinuria reduction and IgA reduction achieved by different anti-APRIL therapies in clinical studies, suggesting JADE-001 could demonstrate superior clinical activity.
• The document references existing IgAN treatments like Filspari, Tarpeyo, and Fabhalta, noting their limitations and the need for disease-modifying therapies.

Stakeholder Impact

• Shareholders of Aerovate and Jade will be impacted by the merger and the resulting ownership structure of the combined company.
• Patients with IgAN may benefit from the development of new and potentially more effective therapies.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Aerovate needs to obtain stockholder approval for the proposed Merger.
• The companies need to complete the proposed concurrent investment.
• Aerovate expects to declare a cash dividend to pre-merger Aerovate stockholders.
• Jade will continue to advance JADE-001 through preclinical and clinical development, with healthy volunteer data expected in 1H 2026.
• The combined company will seek regulatory approvals for JADE-001 and other pipeline candidates.

Key Dates